One-year prophylactic efficacy and safety of pantoprazole in controlling gastro-oesophageal reflux symptoms in patients with healed reflux oesophagitis

Alimentary Pharmacology and Therapeutics

Volumn 11, Issue 6, 1997, Pages 1087-1092

  Mossner J ^a   Koop, H ^b   Porst, H ^c   Wubbolding H ^c   Schneider, A ^a,d   Maier, C ^e  

^a UNIVERSITY HOSPITAL LEIPZIG   (Germany)

^b MARTIN LUTHER KRANKENHAUS   (Germany)

^c Krankenhaus Friedrichstadt   (Germany)

^d Univcrsitatsklinikiim Leipzig ^*  (Germany)

^e ALTANA PHARMA AG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BENZIMIDAZOLE DERIVATIVE; OMEPRAZOLE; PANTOPRAZOLE; PROTON PUMP INHIBITOR;

ADULT; ARTICLE; CLINICAL TRIAL; COLON POLYPOSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; ENDOSCOPY; FEMALE; GASTRIN BLOOD LEVEL; HUMAN; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; REFLUX ESOPHAGITIS; RELAPSE; SURVIVAL RATE; VERTIGO; VOMITING;

EID: 0030732318     PISSN: 02692813     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2036.1997.00242.x     Document Type: Article

References (23)

1. 450 interactions. J Pharmacol Exp Ther 1990; 254: 129-35.
2. Londong W. Effect of pantoprazole on 24-h intragastric pH and serum gastrin in humans. Aliment Pharmacol Ther 1994; 8 (Suppl. 1): 39-46.
3. Schulz H-U, Hartmann M, Steinijans VW, et al. Lack of influence of pantoprazole on the disposition kinetics of theophylline in man. Int J Clin Pharmacol Ther Toxicol 1991: 29: 369-75.
4. Gugler R, Hartmann M, Rudi J, et al. Lack of interaction of pantoprazole and diazepam in man. Gastroenterology 1992; 102 (suppl.): A77.
5. Koop H, Schepp W, Dammann HG, et al. Comparative trial of pantoprazole and ranitidine in the treatment of reflux esophagitis. J Clin Gastroenterol 1995: 20: 192-5.
6. Zeitoun P, Rampal P, Barbier P, et al. Omeprazole (20 mg daily) compared to ranitidine (150mg twice daily) in the treatment of esophagitis caused by reflux. Results of a doubleblind randomized multicenter trial in France and Belgium. Gastroenterol Clin Biol 1989; 13: 457-62.
7. Baldi F, Ferrarini F, Longanesi A, et al. Esophageal function before, during and after healing of erosive esophagitis. Gut 1988; 29: 157-60.
8. Koelz HR, Birchler R. Bretholz A, et al. Healing and relapse of reflux esophagitis during treatment with ranitidine. Gastroenterology 1986; 91: 1198-1205.
9. Armstrong D, Blum AL & the Rezitic Study Group. Full dose H2-receptor antagonist prophylaxis does not prevent relapse of reflux esophagitis. Gut 1989: 30: A1494.
10. Laursen LS, Bondesen S, Hansen J, et al Omeprazole 10 mg or 20 mg daily for the prevention of relapse in gastroesophageal reflux disease. A double-blind comparative study. Gastroenterology 1992: 92: A109.
11. Sontag S, Robinson M, Roufail W, et al Daily omeprazole is needed to maintain healing in erosive esophagitis: a US multicenter double-blind study. Am J Gastroenterol 1992; 87: 1258.
12. Vigneri S, Termini R, Leandro G, et al A comparison of five maintenance therapies for reflux esophagitis. N Engl J Med 1995; 333: 1106-10.
13. Lundell L, Backmann L, Ekstrom P, et al. Prevention of relapse of reflux esophagitis after endoscopie healing: the efficacy and safety of omeprazole compared with ranitidine. Scand J Gastroenterol 1991; 26: 248-56.
14. Mössner J, Kölscher AH,- Herz R, et al A double-blind study of pantoprazole and omeprazole in the treatment of reflux oesophagitis: a multicentre trial. Aliment Pharmacol Ther 1995; 9: 321-6.
15. Müller P, Simon B, Khalil H, et al. Dose-range finding study with the proton pump inhibitor pantoprazole in acute duodenal ulcer patients. Z Gastroenterol 1992; 30: 771-5.
16. Miller RG. Gong G. Munoz A. Survival Analysis. New York: John Wiley & Sons, 1981: 46-52.
17. Klinkenberg-Knol EC, Jansen JBMJ, Lamers CBHW, et al. Temporary cessation of long-term maintenance treatment with omeprazole in patients with H2-receptor-antagonist-resistant reflux esophagitis. Effects on symptoms, endoscopy. serum gastrin and gastric acid output. Scand J Gastroenterol 1990; 25: 1144-50.
18. Toussaint J, Gossuin A, Deruyttere M, et al. Healing and prevention of relapse of reflux esophagitis by cisapride. Gut 1991; 32: 1280-5.
19. Stein DT, Simon TJ, Berlin RG, et al. Controlling 24 hour esophageal acid exposure in patients with healed erosive esophagitis prevents endoscopie recurrence and symptomatic deterioration: results of a 6 month, randomized, double-blind, US, placebo-controlled trial comparing famotidine 20 mg bid and 40 mg bid. Gastroenterology 1991; 100: A167.
20. Bate CM, Booth SN, Crowe JP, et al. Omeprazole 10 mg or 20 mg once daily in the prevention of recurrence of reflux oesophagitis. Gut 1995; 36: 492-8. f
21. Klinkenberg-Knol EC, Festen HPM, Jansen JBMJ, et al. Longterm treatment with omeprazole for refractory reflux esophagitis: efficacy and safety. Ann Intern Med 1994; 121:161-7.
22. Hallerbäck B, Unge P, Carling L, et al. Omeprazole or ranitidine in long-term treatment of reflux esophagitis. Gastroenterology 1994; 107: 1305-11.
23. Koop H, Arnold R. Long-term maintenance treatment of reflux esophagitis with omeprazole. Prospective study in patients with H2-blocker-resistant esophagitis. Dig Dis Sei 1991:36 (5): 552-7.